STSA News and Press, Satsuma Pharmaceuticals Inc. From 09/28/21

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatme...

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatme...

- Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022- - $121.2 million in cash as of June 30, 2021, provides runway into second half of 2023- SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, In...

Satsuma Pharmaceuticals (STSA) announces randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine.The trial of STS101 is a multi-center, single-dose, randomized, double-blind, placebo-controlled, parallel group study in about 1...

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatmen...

SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatmen...

peterschreiber.media/iStock via Getty Images Mizuho has upgraded Satsuma Pharmaceuticals ([[STSA]] +3.1%) to buy from neutral after the company announced Phase 1 data for the migraine treatment STS101. The price target increased to $15.00 per share indicates a premium of ~170.8% to ...

vTv Therapeutics (VTVT) +28% on licensing agreement with Cantex.Adial Pharmaceuticals (ADIL) +22%.Bio-Path Holdings (BPTH) +22% as USPTO grants a new patent.Beyond Air (XAIR) +12%.Sanderson Farms (SAFM) +12% as it explores a potential sale.Idera Pharmaceuticals (IDRA) +11%.Insp...

Midatech Pharma (MTP) +50% on the successful encapsulation of a biologic using Q-Sphera technology.Cellect Biotechnology (APOP) +40%.Clearside Biomedical (CLSD) +23% after filing registration statement for Quoin Pharma merger.Nano-X Imaging (NNOX) +16% after submits 510(k) appl...

Satsuma Pharmaceuticals (STSA) announces positive pharmacokinetic, tolerability and safety results from a Phase 1 trial of migraine treatment STS101.Shares up more than 18% post market.The Phase 1 data showed that all three dose strengths (5.2 mg and two higher dose strengths) ...